Dr Zhang on the Background of a KEYNOTE-564 Subgroup Analysis in RCC

Tian Zhang, MD, MHS, discusses using the adjuvant KEYNOTE-564 regimen to treat high-risk patients with renal cell carcinoma.

Related Keywords

United States ,American , ,Ut Southwestern Medical Center ,Department Of Internal Medicine ,Haroldc Simmons Comprehensive Cancer Center ,American International Kidney Cancer Symposium ,Tian Zhang ,Internal Medicine ,Comprehensive Cancer Center ,Medical Center ,Staging System ,Genitourinary Cancer ,Onclive Tv ,Ut Southwestern Haroldc Simmons Comprehensive Cancer Center ,